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Purpose

Methods

Implications for Practice

The purpose of this DNP project is to determine if the
neuromuscular blockade (NMB) reversal agents neostigmine and
sugammadex affect the incidence of postoperative nausea and
vomiting (PONV).

Eligibility Criteria

• Sugammadex provides more effective reversal and has more
favorable pharmacokinetics

Specific Aims
● Compare PONV rates with neostigmine versus sugammadex
● Determine if pharmacologic decision-making can be justified for
PONV prophylaxis
● Identify gaps in current literature regarding paralytic reversals’
effects on PONV
● Consider confounding factors that could also contribute to
PONV regardless of drug
○ i.e. Female gender, non-smoking status, postoperative opioid
consumption

○ General anesthesia cases with NMBD use
○ Full-text, English, peer-reviewed articles published between 2014-2020

Information Sources & Search
○ Systematic search conducted between August 2019-November 2020
○ PubMed, CINAHL, MEDLINE (EBSCO), Google Scholar
○ Search Terms: “Sugammadex Neostigmine PONV,” “Neuromuscular
blockers and PONV,” “Paralytic reversal agents and PONV”
○ Publication date limited to 2014-2020

Selection of Sources of Evidence
○ Meta-analyses, systematic reviews, randomized controlled trials, case
control studies, or evidence based practice projects
○ Explicit mention of PONV in both groups
○ Abstracts excluded
○ >18 years of age

• Sugammadex has less side effects than neostigmine and
does not require the coadministration of an anticholinergic
• There is not sufficient data suggesting a statistically
significant reduction in PONV when using sugammadex in
comparison to neostigmine
●

PONV alone is not a sufficient reason for the justification of
using sugammadex versus neostigmine
o

Several hospital pharmacies require a rationale for using
sugammadex in order to reduce costs

Data & Synthesis of Results

Background
• PONV is one of the most common postoperative complaints
by patients
• Current prevention of PONV revolves around premedication with antiemetics and minimizing exposure to
triggers
• PONV can initiate a trend of poor outcomes when it
persists, such as delaying patient discharge and increasing
costs
• Pharmacologic agents commonly used in anesthesia can
potentiate PONV
• Neuromuscular blockade (NMB) reversal agents,
sugammadex and neostigmine, can implicate PONV
o High-dose neostigmine, an acetylcholinesterase
inhibitor, has been reported to increase PONV by
stimulating muscarinic receptors and increasing
acetylcholine (AcH), a known PONV trigger, at the
chemoreceptor trigger zone (CTZ)
o Sugammadex has considerable benefits by reducing
adverse drug effects in comparison to neostigmine
through encapsulating the paralytic agent rather than
increasing AcH
• Despite an increased cost with sugammadex, it has
potential to be a rationale for standardized use if PONV can
be linked to neostigmine

○ Charted via an electronic table
○ Variables: incidence of PONV in a sugammadex group; incidence of
PONV in a neostigmine group; incidence of postoperative analgesic
consumption in a sugammadex group; incidence of postoperative
analgesic consumption in a neostigmine group
○ Followed PRISMA statement extension for scoping reviews

Results
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6 of the 8 total studies reviewed did not show a statistically significant
difference in PONV outcomes in neostigmine versus sugammadex reversal
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